MONALEESA-3: Ribociclib plus Fulvestrant in Advanced Hormone-Receptor–Positive, HER2-Negative Breast Cancer

⚠️ Updated analysis. The primary endpoint (investigator-assessed progression-free survival) was previously reported: median PFS 20.5 vs 12.8 months — HR 0.59 (95% CI 0.48–0.73; P<0.001). This analysis reports overall survival at the second prespecified interim analysis, with a median follow-up of 39.4 months.

Key secondary (Overall survival, ITT): NE vs 40.0 months — HR 0.72 (95% CI 0.57–0.92; P=0.00455) Descriptive PFS update (first-line subgroup): 33.6 vs 19.2 months — HR 0.55 (95% CI 0.42–0.72) Safety signal: Grade 3 or 4 neutropenia (57.1% ribociclib vs 0.8% placebo); hepatobiliary toxic effects (13.7% vs 5.8%)

📱 Clinic quick reference: Mobile version — save for point-of-care use

Clinical Bottom Line

Adding ribociclib to fulvestrant demonstrated a statistically significant overall survival advantage over fulvestrant alone in postmenopausal women and men with hormone-receptor–positive, HER2-negative advanced breast cancer. This benefit was observed in both the first-line and second-line/early relapse populations, with a consistent direction of effect across virtually all prespecified subgroups. The OS results crossed the prespecified interim stopping boundary and are considered final per protocol — making MONALEESA-3 one of the pivotal trials establishing a survival benefit for CDK4/6 inhibition in this disease setting.

This trial reinforces CDK4/6 inhibitor–based combination therapy as standard of care for HR-positive, HER2-negative advanced breast cancer. Among the three CDK4/6 inhibitors approved in this setting, ribociclib with fulvestrant now has prospective, formally tested overall survival data from a randomized, double-blind, placebo-controlled trial. Importantly, crossover was not permitted, and despite a quarter of placebo-arm patients receiving subsequent CDK4/6 inhibitor therapy, the survival advantage remained significant — underscoring the magnitude of the benefit.

The principal safety considerations with this regimen remain neutropenia, hepatobiliary toxicity, and QT prolongation. These are manageable with monitoring and dose modifications but require attention at treatment initiation and throughout therapy. The hepatobiliary signal in particular warrants routine liver function testing, and QT monitoring with ECGs is standard per the prescribing information.

Trial Overview

Study Design

• Trial name and registration: MONALEESA-3 (NCT02422615)
• Design: Phase 3, randomized, double-blind, placebo-controlled trial. This publication reports the second prespecified interim analysis of overall survival — the key secondary endpoint. The primary endpoint (investigator-assessed PFS) was previously reported.
• Randomization: 2:1 (ribociclib+fulvestrant : placebo+fulvestrant), stratified by presence or absence of liver or lung metastases and by previous endocrine therapy (previously untreated in the context of advanced disease vs. having received up to one line of endocrine therapy for advanced disease).
• Setting: Advanced (metastatic or locoregionally recurrent) hormone-receptor–positive, HER2-negative breast cancer, first-line or second-line.
• Enrollment period: June 2015 through June 2016.

This publication reports the second prespecified interim analysis of overall survival from the MONALEESA-3 trial. The primary endpoint (investigator-assessed PFS) was previously reported in the original publication [4].

Mechanism of Action

Ribociclib is a selective, small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). In hormone-receptor–positive breast cancer, the cyclin D–CDK4/6 pathway drives cell-cycle progression from G1 to S phase. Ribociclib blocks this transition, inducing G1 arrest and suppressing tumor cell proliferation. It is used in combination with endocrine therapy to enhance the antiproliferative effect [2].

Patient Population

• Key eligibility: Men and postmenopausal women ≥18 years of age; histologically or cytologically confirmed HR-positive, HER2-negative advanced breast cancer (metastatic or locoregionally recurrent, not amenable to curative treatment); ECOG performance status 0 or 1; measurable disease per RECIST v1.1 or at least one predominantly lytic bone lesion; no prior chemotherapy for advanced disease; no prior treatment with fulvestrant or a CDK4/6 inhibitor.
• Biomarker selection: Hormone-receptor–positive, HER2-negative.
• Sample size flow: 726 patients randomized (484 ribociclib+fulvestrant; 242 placebo+fulvestrant). Number screened was not reported in this publication. Safety population size was not reported in this publication (referenced in supplementary Table S7).

Baseline Characteristics

Baseline characteristics were reported in supplementary Table S3, which was not available for this extraction. Detailed baseline characteristics are not reported in this publication's main text.

Treatment Protocol

Experimental Arm: Ribociclib+Fulvestrant (n=484 randomized)

Ribociclib 600 mg orally once daily for 21 consecutive days followed by 7 days off (28-day cycle) plus fulvestrant 500 mg intramuscularly on day 1 of each 28-day cycle with an additional dose on day 15 of cycle 1.

• Dose and schedule: Ribociclib 600 mg orally once daily, 3 weeks on/1 week off; fulvestrant 500 mg IM on day 1 of each 28-day cycle, with additional dose on day 15 of cycle 1.
• Treatment duration: Not reported in this publication.

• Median treatment duration: 15.8 months

• Median relative dose intensity: Not reported in this publication.

Control Arm: Placebo+Fulvestrant (n=242 randomized)

Matching placebo orally once daily for 21 consecutive days followed by 7 days off (28-day cycle) plus fulvestrant 500 mg intramuscularly on day 1 of each 28-day cycle with an additional dose on day 15 of cycle 1.

• Dose and schedule: Matching placebo orally once daily, 3 weeks on/1 week off; fulvestrant 500 mg IM on day 1 of each 28-day cycle, with additional dose on day 15 of cycle 1.
• Treatment duration: Not reported in this publication.
• Median treatment duration: 12.0 months

At the data cutoff (June 3, 2019), 121 of 484 patients (25.0%) in the ribociclib group and 32 of 242 patients (13.2%) in the placebo group were still receiving trial treatment. 362 patients (74.8%) in the ribociclib group and 209 patients (86.4%) in the placebo group had discontinued treatment.

Efficacy Outcomes

The primary endpoint of this trial (investigator-assessed progression-free survival) was reported in the original publication [4]. At the primary analysis, ribociclib plus fulvestrant demonstrated significantly longer PFS than placebo plus fulvestrant: median 20.5 vs 12.8 months; HR 0.59 (95% CI 0.48–0.73; P<0.001). The current analysis, with a median follow-up of 39.4 months (minimum 35.8 months), reports the following updated results:

Key Secondary Endpoint: Overall Survival (Formally Tested)

Definition: Time from randomization to death from any cause. Analysis population: All randomized patients (ITT), N=726. Statistical method: Three-look group sequential design with Lan-DeMets (O'Brien-Fleming) spending function. One-sided type I error controlled at 2.5% via hierarchical testing (PFS tested first; OS tested only if PFS was positive). Median follow-up: 39.4 months (minimum 35.8 months) Data cutoff: June 3, 2019

At the second prespecified interim analysis, 275 deaths had occurred: 167 among 484 patients (34.5%) in the ribociclib group and 108 among 242 patients (44.6%) in the placebo group. This represented approximately 75% of the 351 deaths required for the final analysis.

Ribociclib+Fulvestrant: Median OS not estimable (95% CI 42.5–NE) Placebo+Fulvestrant: Median OS 40.0 months (95% CI 37.0–NE) Comparison: HR 0.72 (95% CI 0.57–0.92; P=0.00455)

The observed P value of 0.00455 crossed the prespecified O'Brien-Fleming stopping boundary threshold of P=0.01129 for the second interim analysis. Per protocol, these OS results are considered final.

Kaplan-Meier estimated overall survival rates: - At 36 months: 67.0% (95% CI 62.4–71.2) in the ribociclib group vs 58.2% (95% CI 51.5–64.3) in the placebo group. - At 42 months: 57.8% (95% CI 52.0–63.2) in the ribociclib group vs 45.9% (95% CI 36.9–54.5) in the placebo group.

For context, the first interim analysis of OS (based on 120 deaths, approximately 34% of the required total) did not cross the stopping boundary (threshold P=0.00013).

Descriptive PFS Update — Overall Population

Analysis population: All randomized patients (ITT) This endpoint was not formally tested in the statistical hierarchy at this data cutoff; it is presented as a descriptive update.

Ribociclib+Fulvestrant: Median 20.6 months (283 events) Placebo+Fulvestrant: Median 12.8 months (193 events) Comparison: HR 0.59 (95% CI 0.49–0.71)

Descriptive PFS Update — First-Line Subgroup

Analysis population: Patients receiving trial treatment as first-line therapy This endpoint was not formally tested in the statistical hierarchy.

Ribociclib+Fulvestrant: Median 33.6 months (95% CI 27.1–41.3; 112 events) Placebo+Fulvestrant: Median 19.2 months (95% CI 14.9–23.6; 95 events) Comparison: HR 0.55 (95% CI 0.42–0.72)

Descriptive PFS Update — Second-Line/Early Relapse Subgroup

Analysis population: Patients receiving second-line therapy or who had early relapse This endpoint was not formally tested in the statistical hierarchy.

Ribociclib+Fulvestrant: Median 14.6 months (167 events) Placebo+Fulvestrant: Median 9.1 months (95 events) Comparison: HR 0.57 (95% CI 0.44–0.74)

Exploratory Endpoints

Overall Survival — First-Line Subgroup

Analysis population: Patients receiving first-line therapy (ribociclib n=237; placebo n=128)

Of the 365 patients who received trial treatment as first-line therapy, deaths occurred in 63 of 237 patients (26.6%) in the ribociclib group and 47 of 128 patients (36.7%) in the placebo group.

Ribociclib+Fulvestrant: Median OS not reached Placebo+Fulvestrant: Median OS 45.1 months Comparison: HR 0.70 (95% CI 0.48–1.02)

Estimated OS at 42 months: 66.9% (95% CI 58.7–73.9) in the ribociclib group vs 56.3% (95% CI 44.2–66.8) in the placebo group.

Overall Survival — Second-Line/Early Relapse Subgroup

Analysis population: Patients receiving second-line therapy or who had early relapse (ribociclib n=237; placebo n=109)

Of the 346 patients in this subgroup, deaths occurred in 102 of 237 patients (43.0%) in the ribociclib group and 60 of 109 patients (55.0%) in the placebo group.

Ribociclib+Fulvestrant: Median OS 40.2 months Placebo+Fulvestrant: Median OS 32.5 months Comparison: HR 0.73 (95% CI 0.53–1.00)

Time to First Subsequent Chemotherapy

Analysis population: All randomized patients

Ribociclib+Fulvestrant: Median not reached (182 events) Placebo+Fulvestrant: Median 29.5 months (115 events) Comparison: HR 0.70 (95% CI 0.55–0.88)

Estimates for the percentage of patients who had not yet received chemotherapy at 42 months were 56.4% (95% CI 51.3–61.1) in the ribociclib group and 43.7% (95% CI 36.3–50.8) in the placebo group.

Progression-Free Survival 2 (PFS2)

PFS2 results were reported in supplementary Figure S3, which was not available for this extraction. Median values and hazard ratios are not reported in this publication's main text.

Safety

Safety Population

The safety population size per arm was not explicitly reported in the main text of this publication. Full safety data were referenced in supplementary Table S7, which was not available for this extraction. The publication states that adverse events were consistent with those in the primary report, and no new safety signals were observed.

Safety Summary

Fewer than 4 standard summary safety metrics (any AE, grade ≥3 AE, serious AE, treatment-related AE, discontinuation due to AE, dose reduction) were reported in this publication. The following standard metrics were not reported in this publication: any-grade AE rate, overall grade ≥3 AE rate, serious AE rate, treatment-related AE rate, discontinuation due to AE rate, dose reduction rate, dose interruption rate, and treatment-related death rate. These data are referenced in supplementary Table S7.

Grade ≥3 Adverse Events of Clinical Significance

The source reports grade 3 and grade 4 combined for these events:

Adverse Events of Special Interest

⚠️ Hepatobiliary Toxic Effects: Critical Safety Signal

• Any grade: Not reported in this publication
• Grade 3 or 4: 13.7% (ribociclib) vs 5.8% (placebo)
• Clinical implication: Routine monitoring of liver function tests is required. Hepatobiliary toxicity occurred at a meaningful rate even in the placebo arm, but was substantially more frequent with ribociclib. Dose modifications per the prescribing information should be followed for LFT elevations.

Prolonged QT Interval

• Any grade: Not reported in this publication
• Grade 3 or 4: 3.1% (ribociclib) vs 1.2% (placebo)
• Clinical implication: ECG monitoring is required at baseline, at approximately day 14 of cycle 1, and at the beginning of cycle 2, and as clinically indicated thereafter per the prescribing information [2]. Ribociclib should be avoided with concomitant QT-prolonging medications.

Interstitial Lung Disease

• Grade 3 or 4: 0.2% (1 patient) (ribociclib) vs 0% (placebo)
• Clinical implication: Rare but important; clinicians should be aware and monitor for respiratory symptoms.

Deaths

• Total deaths: 275 (167 in the ribociclib group [34.5%]; 108 in the placebo group [44.6%])
• Treatment-related deaths: Not reported in this publication.

Subgroup Analyses

The forest plot (Figure 2) reported overall survival hazard ratios across multiple prespecified subgroups. Interaction p-values were not reported for any subgroup. These subgroup analyses were not powered for formal statistical comparisons. Results should be interpreted as hypothesis-generating.

The direction of the OS benefit consistently favored ribociclib across nearly all subgroups. The Asian subgroup (HR 1.42; 95% CI 0.46–4.33; n=63) and Other race subgroup (HR 1.26; 95% CI 0.23–6.83; n=22) are notable exceptions, though both had very small sample sizes and wide confidence intervals that preclude meaningful interpretation.

Key Comparator Trials

Cross-trial comparisons are limited by differences in patient populations, trial designs, and endpoints. These data are presented for context, not for direct statistical comparison.

Contextual Notes

MONALEESA-3 is distinct from PALOMA-3 and MONARCH 2 in its inclusion of both first-line and second-line patients. PALOMA-3 and MONARCH 2 enrolled only patients with disease progression on prior endocrine therapy. This broader population in MONALEESA-3 provides unique data on the first-line use of a CDK4/6 inhibitor with fulvestrant.

All three CDK4/6 inhibitors (ribociclib, palbociclib, abemaciclib) have demonstrated PFS benefits with fulvestrant, but OS data have varied in strength and significance across the programs. MONALEESA-3 crossed its prespecified OS interim boundary with a formally tested P value, and crossover was not permitted — two design features that strengthen the interpretation of the survival benefit. The MONARCH 2 trial also demonstrated a statistically significant OS improvement with abemaciclib plus fulvestrant. PALOMA-3 OS results should be consulted in the original publication [5].

Differences in toxicity profiles among the three CDK4/6 inhibitors (neutropenia rates, diarrhea with abemaciclib, QT prolongation with ribociclib, hepatotoxicity) may influence agent selection in practice and should be weighed alongside efficacy data.

Grey Zones and Unanswered Questions

• Men with advanced breast cancer: MONALEESA-3 enrolled men and postmenopausal women, but the proportion of male patients and their specific outcomes are not reported in this publication. Whether the survival benefit extends equally to men remains uncertain, though eligibility was inclusive.

• Optimal CDK4/6 inhibitor selection: The trial compared ribociclib+fulvestrant to fulvestrant alone but did not compare ribociclib to other CDK4/6 inhibitors (palbociclib, abemaciclib). There are no prospective head-to-head comparisons among the three agents; clinical selection is guided by toxicity profile, patient comorbidities, and practical considerations.

• Sequencing after CDK4/6 inhibitor progression: Only 11.0% of patients in the ribociclib group who discontinued received subsequent CDK4/6 inhibitor therapy, compared to 25.4% in the placebo group. The role of CDK4/6 inhibitor re-challenge or sequencing with novel agents (PI3K inhibitors, oral SERDs, antibody-drug conjugates) after CDK4/6 inhibitor progression was not addressed by this trial.

• Patients with prior CDK4/6 inhibitor exposure: The trial excluded patients with any prior CDK4/6 inhibitor therapy. With CDK4/6 inhibitors now standard in the adjuvant setting (monarchE), an increasing proportion of patients presenting with metastatic disease will have had prior CDK4/6 inhibitor exposure — a population this trial does not inform.

• Longer-term survival outcomes: Although the second interim OS analysis crossed the stopping boundary and is considered final per protocol, only approximately 75% of the required OS events had occurred (275 of 351). Whether the magnitude of the survival benefit is maintained, increases, or diminishes with longer follow-up — particularly in the first-line subgroup where median OS had not yet been reached in the ribociclib arm — remains an open question.

Clinical Implications

Where This Fits in the Treatment Sequence

MONALEESA-3 supports the use of ribociclib plus fulvestrant in both the first-line and second-line settings for postmenopausal patients with HR-positive, HER2-negative advanced breast cancer. In current practice, CDK4/6 inhibitor–based combination therapy is established as the standard first-line approach for this population. NCCN guidelines [3] recommend CDK4/6 inhibitors (ribociclib, palbociclib, or abemaciclib) in combination with endocrine therapy as preferred first-line and second-line options.

The MONALEESA-3 survival data are particularly relevant for patients in whom fulvestrant is chosen as the endocrine partner — including patients who have progressed on or shortly after adjuvant aromatase inhibitor therapy. For first-line patients, ribociclib plus fulvestrant is a well-supported alternative to ribociclib plus an aromatase inhibitor (MONALEESA-2 data) or letrozole plus a CDK4/6 inhibitor.

Practical Considerations

• Neutropenia monitoring: With grade 3 or 4 neutropenia at 57.1%, CBCs are essential before each cycle, particularly in the first several months of therapy.
• Hepatic monitoring: Grade 3 or 4 hepatobiliary toxic effects at 13.7% require liver function testing at baseline, every 2 weeks for the first 2 cycles, then monthly per the prescribing information [2].
• QT monitoring: ECGs should be performed at baseline, at approximately day 14 of cycle 1, at the beginning of cycle 2, and as clinically indicated [2]. Avoid concomitant strong CYP3A inhibitors and QT-prolonging medications.
• Treatment duration: There was no prespecified limit on treatment duration. Patients continued until disease progression, unacceptable toxicity, or withdrawal of consent.

Post-Progression Options

Subsequent antineoplastic therapy was received by 295 of 362 patients (81.5%) in the ribociclib group and 177 of 209 patients (84.7%) in the placebo group who discontinued treatment. Chemotherapy, alone or in combination, was received as the first subsequent therapy by 205 of the 571 patients who discontinued trial treatment — 130 of 362 patients (35.9%) in the ribociclib group and 75 of 209 patients (35.9%) in the placebo group. Notably, 53 of 209 patients (25.4%) in the placebo group received subsequent CDK4/6 inhibitor therapy compared to 40 of 362 patients (11.0%) in the ribociclib group. Despite this differential access to post-trial CDK4/6 inhibitor therapy favoring the placebo arm, the OS benefit for ribociclib remained statistically significant.

Unanswered Questions

The two most practice-relevant open questions are: (1) How to sequence therapy after CDK4/6 inhibitor progression, as novel agents (PI3K inhibitors, oral SERDs, ADCs, AKT inhibitors) become available; and (2) Whether the survival benefit applies to patients who have received prior CDK4/6 inhibitor therapy in the adjuvant setting — an increasingly common clinical scenario.

Regulatory and Guideline Status

Regulatory

• FDA: Ribociclib (Kisqali) is approved in combination with fulvestrant for the treatment of postmenopausal women and men with HR-positive, HER2-negative advanced or metastatic breast cancer as initial endocrine-based therapy or following disease progression on endocrine therapy. The MONALEESA-3 trial was a key supporting study for this indication. Regulatory status should be verified with current FDA/EMA labeling.
• EMA: Ribociclib is approved in combination with fulvestrant for the treatment of women with HR-positive, HER2-negative locally advanced or metastatic breast cancer. Regulatory status should be verified with current EMA labeling.

⚠️ Regulatory status verified as of March 2026. Confirm current approval status and labeled indications before clinical use at FDA.gov.

Guidelines

• NCCN: Ribociclib plus fulvestrant is listed as a preferred first-line and second-line option for HR-positive, HER2-negative metastatic breast cancer in the NCCN Clinical Practice Guidelines [3].

Companion Diagnostics

The trial required HR-positive, HER2-negative status by standard pathology testing. No specific companion diagnostic was mandated beyond standard ER/PR immunohistochemistry and HER2 testing (IHC/ISH).

About the Author

Andrew Stevenson is the founder and systems architect of kill-cancer.com, a clinical intelligence platform delivering structured, source-traced oncology trial analysis to practicing clinicians. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces directly to its source publication. Zero calculation. Zero editorializing. Zero hallucination.

Five siblings lost to cancer built the urgency. The engineering builds the trust.

📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum

Disclaimer

This article is intended for healthcare professionals only. It is not medical advice and should not be used as a substitute for professional clinical judgment. Treatment decisions should be made in consultation with qualified healthcare providers based on individual patient circumstances.

All trial data presented in this article are sourced directly from the published clinical trial report and its supplementary materials. Numbers are reproduced exactly as reported; no calculations, derivations, or estimates have been performed.

Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability.

Comparator trial data presented in Section 8 are sourced from their respective published reports and are provided for contextual purposes only. Cross-trial comparisons have inherent limitations and should not be interpreted as direct statistical comparisons.

References

1. Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514-524. doi:10.1056/NEJMoa1911149
2. Kisqali (ribociclib) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2026. Accessed March 2026.
4. Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465-2472.
5. Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926-1936.
6. Sledge GW Jr, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy — MONARCH 2. JAMA Oncol. 2020;6(1):116-124.